MORI, MATTEO
MORI, MATTEO
Dipartimento di Scienze Farmaceutiche
Nanoenabling MbtI Inhibitors for Next-Generation Tuberculosis Therapy
2025 G. Cazzaniga, M. Mori, A. Griego, E. Scarpa, G. Moschetti, S. Muzzioli, G. Stelitano, L.R. Chiarelli, M. Cocorullo, E. Casali, A. Porta, G. Zanoni, A. Tresoldi, E. Pini, Í.L. Batalha, G. Battaglia, T. Tuccinardi, L. Rizzello, S. Villa, F. Meneghetti
Synthesis and crystallographic investigation of two new neutral Ir(III) complexes bearing 6-(phenyl)phenanthridine ligands
2025 L. Menduti, M. Mori, X. Zhou, N. Quadrio, F. Meneghetti, L. De Cola
Enhancing the activity of γ-hydroxy lactone derivatives as innovative peroxisome proliferator-activated receptor γ non-agonists inhibiting cyclin-dependent kinase 5-mediated phosphorylation
2025 G. Cazzaniga, D. Capelli, R. Montanari, E.M.A. Fassi, G. Grazioso, A. Tresoldi, F. Rinaldi, E. Calleri, I. Bassanini, S. Romeo, M. Garofalo, M. Mori, F. Meneghetti, S. Villa
Novel quinazolinones active against multidrug‐resistant Mycobacterium tuberculosis: synthesis, antimicrobial evaluation and in silico exploration of PonA1 as a potential target
2025 M. Kerda, D. Nawrot, P. Slechta, M. Domanský, A. Askari, H. Kamangar, O. Janďourek, K. Konečná, P. Paterová, I. Hlbočanová, M. Macháček, M. Mori, F. Meneghetti, M. Doležal, J. Zitko, G. Bouz
Exploring the Inhibition of Iron Acquisition in M. abscessus as a Potential Anti-Virulence Strategy in People with Cystic Fibrosis
2024 M. Mori, A. Tresoldi, G. Cazzaniga, A. Gelain, G. Stelitano, M. Cocorullo, L.R. Chiarelli, P. Delre, G.F. Mangiatordi, A. Cassetta, S. Covaceuszach, S. Villa, F. Meneghetti
Targeting iron acquisition in M. abscessus: a new strategy for the development of anti-virulence agents for cystic fibrosis patients
2024 M. Mori, A. Tresoldi, G. Cazzaniga, A. Gelain, G. Stelitano, M. Cocorullo, L.R. Chiarelli, P. Delre, G.F. Mangiatordi, A. Cassetta, S. Covaceuszach, S. Villa, F. Meneghetti
Towards a safe treatment of Insulin Resistance: γ-hydroxy lactone-based derivatives as PPARγ non-agonists
2024 G. Cazzaniga, M. Mori, D. Capelli, R. Montanari, A. Laghezza, F. Loiodice, E.M.A. Fassi, G. Grazioso, F. Meneghetti, S. Villa
Anti-biofilm efficacy of novel silica-based nanoparticles functionalized withnatural derivatives for surface coating
2024 G. Cazzaniga, C. Catto', M. Mori, P. Hayes, D. Yan, N.H. Arachchi, F. Villa, F. Cappitelli, A. Melocchi, L. Zema, S. Crespi, P.J. Molino, S. Villa, A. Gelain
Eco-Friendly Bio-Based Solvents for the Acetylation of the Amino Group of Amino Acids
2024 G. Cazzaniga, A. Tresoldi, A. Gelain, F. Meneghetti, M. Mori, S. Villa
Synthesis and Analytical Characterization of Cyclization Products of 3-Propargyloxy-5-benzyloxy-benzoic Acid Methyl Ester
2024 M. Mori, G. Cazzaniga, D. Nava, E. Pini
A hit expansion of 3-benzamidopyrazine-2-carboxamide: Toward inhibitors of prolyl-tRNA synthetase with antimycobacterial activity
2024 V. Sukanth Kumar Pallabothula, N. Taimur Abdalrahman, M. Mori, A. Hossein Fekri, O. Janďourek, K. Konečná, P. Paterová, M. Novák, P. Dudášová-Hatoková, P. Štěrbová-Kovaříková, C. Castellano, F. Meneghetti, S. Villa, J. Kuneš, M. Juhás, J. Zitko
Structural basis for specific inhibition of salicylate synthase from Mycobacterium abscessus
2024 M. Mori, M. Cocorullo, A. Tresoldi, G. Cazzaniga, A. Gelain, G. Stelitano, L.R. Chiarelli, M. Tomaiuolo, P. Delre, G.F. Mangiatordi, M. Garofalo, A. Cassetta, S. Covaceuszach, S. Villa, F. Meneghetti
Structural Study of a New MbtI-Inhibitor Complex: Towards an Optimized Model for Structure-Based Drug Discovery
2023 M. Mori, S. Villa, L.R. Chiarelli, F. Meneghetti, M. Bellinzoni
Discovery of novel SIRT5 activators as potential anti-inflammatory agents
2023 A. Gelain, . Mori, G. Cazzaniga, F. Meneghetti, . Wong, L. Jun Yan, P.S. Coghi, S. Villa
Ironing out Fe3+ acquisition in M. abscessus: a new strategy to target virulence factors in non-tuberculous mycobacteria
2023 M. Mori, A. Tresoldi, G. Cazzaniga, A. Gelain, G. Stelitano, M. Cocorullo, L.R. Chiarelli, P. Delre, G.F. Mangiatordi, A. Cassetta, S. Covaceuszach, S. Villa, F. Meneghetti
γ-HYDROXY LACTONE BASED PPARγ NON-AGONISTS AS SAFE AND INNOVATIVE ANTI-DIABETIC AGENTS
2023 G. Cazzaniga, M. Mori, D. Capelli, R. Montanari, A. Laghezza, F. Loiodice, I. Bassanini, S. Romeo, E.M.A. Fassi, G. Grazioso, M. Quaglia, F. Meneghetti, S. Villa
Natural and nature-inspired compounds targeting E. coli WrbA as antibiofilm agents: computational studies, synthesis, and biological evaluation
2023 M. Mori, S. Villa, A. Ratti, F. Meneghetti, G. Roda, A. Gelain, F. Villa, E.M.A. Fassi, F. Forlani, G. Grazioso
γ-hidroxy-lactone derivatives as ppar-γ non-agonists blocking cdk5-mediated phosporylation for a safer anti-diabetic treatment
2023 G. Cazzaniga, M. Mori, D. Capelli, R. Montanari, A. Laghezza, F. Loiodice, I. Bassanini, S. Romeo, E.M.A. Fassi, M. Quaglia, G. Grazioso, F. Meneghetti, S. Villa
γ-HYDROXY LACTONE BASED PPARγ NON-AGONISTS AS SAFE AND INNOVATIVE ANTI-DIABETIC AGENTS.
2023 G. Cazzaniga, M. Mori, D. Capelli, R. Montanari, A. Laghezza, F. Loiodice, I. Bassanini, S. Romeo, E.M.A. Fassi, G. Grazioso, M. Quaglia, F. Meneghetti, S. Villa
Optimizing the drug discovery process for the development of MbtI inhibitors as promising anti-virulence agents against TB
2023 M. Mori, G. Cazzaniga, A. Tresoldi, A. Gelain, L.R. Chiarelli, G. Stelitano, M. Bellinzoni, S. Villa, F. Meneghetti